ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

INS.GB Instem Plc

0.00
0.00 (0.00%)
- - Closed
Realtime Data
Share Name Share Symbol Market Type Share ISIN Share Description
Instem Plc AQSE:INS.GB Aquis Stock Exchange Ordinary Share GB00B3TQCK30
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Instem plc Appointment of Chief Operating Officer

09/01/2017 2:30pm

RNS Non-Regulatory


TIDMINS

Instem plc

09 January 2017

9 January 2017

Instem plc

("Instem" or the "Company" or the "Group")

Appointment of Chief Operating Officer

Instem (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces the appointment of Ms. MaryBeth Thompson as Chief Operating Officer of the Group with immediate effect. Ms. Thompson, who has not been appointed to the Instem plc main Board, will report to Phil Reason, CEO.

Ms. Thompson has more than 18 years of experience in the life sciences industry, with a primary focus in Regulatory Affairs and Operations with a demonstrable track record as a leader and builder of outsourcing services businesses.

During her tenure at PAREXEL International ("PAREXEL"), a multinational life sciences consulting firm, and its predecessor organisations LIQUENT and CDC Solutions, she established and expanded the regulatory outsourcing services practice from a $1 million revenue business with 30 employees to an international organisation across the US, Europe and India with more than $30 million of revenues and 300 employees.

Prior to PAREXEL, Ms. Thompson worked for AstraZeneca and Wyeth-Ayerst Laboratories in pharmaceutical product development, where she held a range of senior regulatory positions.

Phil Reason, CEO of Instem, commented: "We are delighted to have appointed someone of MaryBeth's calibre and experience to Instem. MaryBeth has a strong track record in building life sciences businesses and we look forward to the benefits she will bring as we embark upon the Company's next phase of growth."

For further information, please contact:

 
 Instem plc               +44 (0) 1785 825 600 
 Phil Reason, CEO 
 Nigel Goldsmith, CFO 
 
 N+1 Singer (Nominated 
  Adviser & Broker)       +44 (0) 20 7496 3000 
 Richard Lindley 
  Nick Owen 
 
 Walbrook Financial PR    +44 (0) 20 7933 8000 
 Paul Cornelius           instem@walbrookpr.com 
 Helen Cresswell 
  Sam Allen 
  Paul Whittington 
 
 

About Instem

About Instem plc

Instem is a leading supplier of IT applications and services to the early development healthcare market delivering compelling solutions for data collection, analysis and regulatory submissions management. Instem solutions are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

To learn more about Instem solutions and its mission, please visit www.instem.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUGUAPGUPMGCB

(END) Dow Jones Newswires

January 09, 2017 09:30 ET (14:30 GMT)

1 Year Instem Chart

1 Year Instem Chart

1 Month Instem Chart

1 Month Instem Chart

Your Recent History

Delayed Upgrade Clock